Integrated analysis of the genomic instability of PTEN in clinically insignificant and significant prostate cancer

Stephen J. Murphy; Robert J. Karnes; Farhad Kosari; B. Edgardo R.Parilla Castellar; Benjamin R. Kipp; Sarah H. Johnson; Simone Terra; Faye R. Harris; Geoffrey C. Halling; Janet L.Schaefer Klein; Aqsa Nasir; Eric Bergstrahl; Laureano J. Rangel; William R. Sukov; George Vasmatzis; John C. Cheville

doi:10.1038/modpathol.2015.136

Integrated analysis of the genomic instability of PTEN in clinically insignificant and significant prostate cancer

Stephen J. Murphy, Robert J. Karnes, Farhad Kosari, B. Edgardo R.Parilla Castellar, Benjamin R. Kipp, Sarah H. Johnson, Simone Terra, Faye R. Harris, Geoffrey C. Halling, Janet L.Schaefer Klein, Aqsa Nasir, Eric Bergstrahl, Laureano J. Rangel, William R. Sukov, George Vasmatzis, John C. Cheville

Research output: Contribution to journal › Article › peer-review

23 Scopus citations

Abstract

Patients with clinically insignificant prostate cancer remain a major over-treated population. PTEN loss is one of the most recurrent alterations in prostate cancer associated with an aggressive phenotype, however, the occurrence of PTEN loss in insignificant prostate cancer has not been reported and its role in the separation of insignificant from significant prostate cancer is unclear. An integrated analysis of PTEN loss was, therefore, performed for structural variations, point mutations and protein expression in clinically insignificant (48 cases) and significant (76 cases) prostate cancers treated by radical prostatectomy. Whole-genome mate pair sequencing was performed on tumor cells isolated by laser capture microdissection to characterize PTEN structural alterations. Fluorescence in situ hybridization probes were constructed from the sequencing data to detect the spectrum of these PTEN alterations. PTEN loss by mate pair sequencing and fluorescence in situ hybridization occurred in 2% of insignificant, 13% of large volume Gleason score 6, and 46% of Gleason score 7 and higher cancers. In Gleason score 7 cancers with PTEN loss, PTEN alterations were detected in both Gleason pattern 3 and 4 in 57% of cases by mate pair sequencing, 75% by in situ hybridization and 86% by immunohistochemistry. PTEN loss by sequencing was strongly associated with TMPRSS2-ERG fusion, biochemical recurrence, PTEN loss by in situ hybridization and protein loss by immunohistochemistry. The complex nature of PTEN rearrangements was unveiled by sequencing, detailing the heterogeneous events leading to homozygous loss of PTEN. PTEN point mutation was present in 5% of clinically significant tumors and not in insignificant cancer or high-grade prostatic intraepithelial neoplasia. PTEN loss is infrequent in clinically insignificant prostate cancer, and is associated with higher grade tumors. Detection of PTEN loss in Gleason score 6 cancer in a needle biopsy specimen indicates a higher likelihood of clinically significant prostate cancer.

Original language	English (US)
Pages (from-to)	143-156
Number of pages	14
Journal	Modern Pathology
Volume	29
Issue number	2
DOIs	https://doi.org/10.1038/modpathol.2015.136
State	Published - Feb 1 2016

ASJC Scopus subject areas

Pathology and Forensic Medicine

Access to Document

10.1038/modpathol.2015.136

Cite this

Murphy, S. J., Karnes, R. J., Kosari, F., Castellar, B. E. R. P., Kipp, B. R., Johnson, S. H., Terra, S., Harris, F. R., Halling, G. C., Klein, J. L. S., Nasir, A., Bergstrahl, E., Rangel, L. J., Sukov, W. R., Vasmatzis, G., & Cheville, J. C. (2016). Integrated analysis of the genomic instability of PTEN in clinically insignificant and significant prostate cancer. Modern Pathology, 29(2), 143-156. https://doi.org/10.1038/modpathol.2015.136

Murphy, SJ , Karnes, RJ , Kosari, F, Castellar, BERP, Kipp, BR, Johnson, SH, Terra, S, Harris, FR, Halling, GC, Klein, JLS, Nasir, A, Bergstrahl, E, Rangel, LJ, Sukov, WR, Vasmatzis, G & Cheville, JC 2016, 'Integrated analysis of the genomic instability of PTEN in clinically insignificant and significant prostate cancer', Modern Pathology, vol. 29, no. 2, pp. 143-156. https://doi.org/10.1038/modpathol.2015.136

@article{bc1fa674e9334fd59d30b9e03d12a09d,

title = "Integrated analysis of the genomic instability of PTEN in clinically insignificant and significant prostate cancer",

abstract = "Patients with clinically insignificant prostate cancer remain a major over-treated population. PTEN loss is one of the most recurrent alterations in prostate cancer associated with an aggressive phenotype, however, the occurrence of PTEN loss in insignificant prostate cancer has not been reported and its role in the separation of insignificant from significant prostate cancer is unclear. An integrated analysis of PTEN loss was, therefore, performed for structural variations, point mutations and protein expression in clinically insignificant (48 cases) and significant (76 cases) prostate cancers treated by radical prostatectomy. Whole-genome mate pair sequencing was performed on tumor cells isolated by laser capture microdissection to characterize PTEN structural alterations. Fluorescence in situ hybridization probes were constructed from the sequencing data to detect the spectrum of these PTEN alterations. PTEN loss by mate pair sequencing and fluorescence in situ hybridization occurred in 2% of insignificant, 13% of large volume Gleason score 6, and 46% of Gleason score 7 and higher cancers. In Gleason score 7 cancers with PTEN loss, PTEN alterations were detected in both Gleason pattern 3 and 4 in 57% of cases by mate pair sequencing, 75% by in situ hybridization and 86% by immunohistochemistry. PTEN loss by sequencing was strongly associated with TMPRSS2-ERG fusion, biochemical recurrence, PTEN loss by in situ hybridization and protein loss by immunohistochemistry. The complex nature of PTEN rearrangements was unveiled by sequencing, detailing the heterogeneous events leading to homozygous loss of PTEN. PTEN point mutation was present in 5% of clinically significant tumors and not in insignificant cancer or high-grade prostatic intraepithelial neoplasia. PTEN loss is infrequent in clinically insignificant prostate cancer, and is associated with higher grade tumors. Detection of PTEN loss in Gleason score 6 cancer in a needle biopsy specimen indicates a higher likelihood of clinically significant prostate cancer.",

author = "Murphy, {Stephen J.} and Karnes, {Robert J.} and Farhad Kosari and Castellar, {B. Edgardo R.Parilla} and Kipp, {Benjamin R.} and Johnson, {Sarah H.} and Simone Terra and Harris, {Faye R.} and Halling, {Geoffrey C.} and Klein, {Janet L.Schaefer} and Aqsa Nasir and Eric Bergstrahl and Rangel, {Laureano J.} and Sukov, {William R.} and George Vasmatzis and Cheville, {John C.}",

year = "2016",

month = feb,

day = "1",

doi = "10.1038/modpathol.2015.136",

language = "English (US)",

volume = "29",

pages = "143--156",

journal = "Modern Pathology",

issn = "0893-3952",

publisher = "Nature Publishing Group",

number = "2",

}

TY - JOUR

T1 - Integrated analysis of the genomic instability of PTEN in clinically insignificant and significant prostate cancer

AU - Murphy, Stephen J.

AU - Karnes, Robert J.

AU - Kosari, Farhad

AU - Castellar, B. Edgardo R.Parilla

AU - Kipp, Benjamin R.

AU - Johnson, Sarah H.

AU - Terra, Simone

AU - Harris, Faye R.

AU - Halling, Geoffrey C.

AU - Klein, Janet L.Schaefer

AU - Nasir, Aqsa

AU - Bergstrahl, Eric

AU - Rangel, Laureano J.

AU - Sukov, William R.

AU - Vasmatzis, George

AU - Cheville, John C.

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Patients with clinically insignificant prostate cancer remain a major over-treated population. PTEN loss is one of the most recurrent alterations in prostate cancer associated with an aggressive phenotype, however, the occurrence of PTEN loss in insignificant prostate cancer has not been reported and its role in the separation of insignificant from significant prostate cancer is unclear. An integrated analysis of PTEN loss was, therefore, performed for structural variations, point mutations and protein expression in clinically insignificant (48 cases) and significant (76 cases) prostate cancers treated by radical prostatectomy. Whole-genome mate pair sequencing was performed on tumor cells isolated by laser capture microdissection to characterize PTEN structural alterations. Fluorescence in situ hybridization probes were constructed from the sequencing data to detect the spectrum of these PTEN alterations. PTEN loss by mate pair sequencing and fluorescence in situ hybridization occurred in 2% of insignificant, 13% of large volume Gleason score 6, and 46% of Gleason score 7 and higher cancers. In Gleason score 7 cancers with PTEN loss, PTEN alterations were detected in both Gleason pattern 3 and 4 in 57% of cases by mate pair sequencing, 75% by in situ hybridization and 86% by immunohistochemistry. PTEN loss by sequencing was strongly associated with TMPRSS2-ERG fusion, biochemical recurrence, PTEN loss by in situ hybridization and protein loss by immunohistochemistry. The complex nature of PTEN rearrangements was unveiled by sequencing, detailing the heterogeneous events leading to homozygous loss of PTEN. PTEN point mutation was present in 5% of clinically significant tumors and not in insignificant cancer or high-grade prostatic intraepithelial neoplasia. PTEN loss is infrequent in clinically insignificant prostate cancer, and is associated with higher grade tumors. Detection of PTEN loss in Gleason score 6 cancer in a needle biopsy specimen indicates a higher likelihood of clinically significant prostate cancer.

AB - Patients with clinically insignificant prostate cancer remain a major over-treated population. PTEN loss is one of the most recurrent alterations in prostate cancer associated with an aggressive phenotype, however, the occurrence of PTEN loss in insignificant prostate cancer has not been reported and its role in the separation of insignificant from significant prostate cancer is unclear. An integrated analysis of PTEN loss was, therefore, performed for structural variations, point mutations and protein expression in clinically insignificant (48 cases) and significant (76 cases) prostate cancers treated by radical prostatectomy. Whole-genome mate pair sequencing was performed on tumor cells isolated by laser capture microdissection to characterize PTEN structural alterations. Fluorescence in situ hybridization probes were constructed from the sequencing data to detect the spectrum of these PTEN alterations. PTEN loss by mate pair sequencing and fluorescence in situ hybridization occurred in 2% of insignificant, 13% of large volume Gleason score 6, and 46% of Gleason score 7 and higher cancers. In Gleason score 7 cancers with PTEN loss, PTEN alterations were detected in both Gleason pattern 3 and 4 in 57% of cases by mate pair sequencing, 75% by in situ hybridization and 86% by immunohistochemistry. PTEN loss by sequencing was strongly associated with TMPRSS2-ERG fusion, biochemical recurrence, PTEN loss by in situ hybridization and protein loss by immunohistochemistry. The complex nature of PTEN rearrangements was unveiled by sequencing, detailing the heterogeneous events leading to homozygous loss of PTEN. PTEN point mutation was present in 5% of clinically significant tumors and not in insignificant cancer or high-grade prostatic intraepithelial neoplasia. PTEN loss is infrequent in clinically insignificant prostate cancer, and is associated with higher grade tumors. Detection of PTEN loss in Gleason score 6 cancer in a needle biopsy specimen indicates a higher likelihood of clinically significant prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=84956632580&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84956632580&partnerID=8YFLogxK

U2 - 10.1038/modpathol.2015.136

DO - 10.1038/modpathol.2015.136

M3 - Article

C2 - 26612463

AN - SCOPUS:84956632580

SN - 0893-3952

VL - 29

SP - 143

EP - 156

JO - Modern Pathology

JF - Modern Pathology

IS - 2

ER -

Integrated analysis of the genomic instability of PTEN in clinically insignificant and significant prostate cancer

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this